ISRG
Still growing, just with a lighter foot on the pedal
Intuitive Surgical is basically telling investors: the da Vinci robot is still a growth machine, but 2026 won’t look quite as turbocharged as 2025. The company is guiding for 13% to 15% procedure growth next year, after posting nearly 18% growth in 2025.
Why that matters to your portfolio
For a premium-valued stock like ISRG, the market usually expects the story to stay shiny and fast. So even though this is still healthy growth, the slowdown can matter because it raises the usual annoying investor questions: Is the adoption curve maturing? Is U.S. general surgery growth getting harder to squeeze out? And how much can international expansion really carry the load?
The fine print hiding under the robot arm
The upside case is still there. Intuitive says growth should keep getting help from:
- broader U.S. general surgery adoption
- continued international expansion
But there are real risks hanging around the operating room too:
- U.S. reimbursement changes could crimp procedure economics
- global market pressure could make growth a little less effortless than bulls would like
Big picture: this is not a doom-and-gloom update. It’s more like a Ferrari saying it’ll still be fast next year, just maybe not quite as dramatic when it punches the gas.